Vivani Medical, Inc. VANI recently announced the filing of a Form 10 registration statement with the U.S. Securities and ...

Obesity — like most other medical conditions — requires an “arsenal” of treatments, rather than a one-size-fits-all approach.

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

May 27, 2025 — A new study suggests that boys who become overweight in their early teens risk damaging the genes of their future children, increasing their chances of developing asthma, obesity ...

In recent years, overweight and obesity have become a serious global health problem, posing significant risk factors for various diseases. Longing for a civilized and healthy lifestyle ...

This can be explained by the first generation weight loss product that Novo Nordisk had launched, Saxenda (liraglutide), which had been approved by the FDA to treat obesity in 2014. The product ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

June 6, 2025 • Today:Last year, climate activists Parke Wilde, Julia Hansen, and Peter Watson were arrested protesting the proposed expansion of Bedford’s Hanscom Field – the second busiest ...

Lilly and rival Novo Nordisk revolutionized diabetes and obesity treatment over the last few years with GLP-1 medicines that opened up one of the biggest markets the pharmaceutical industry has ever ...